Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.46M-$1.46MderivedN/M vs Q4 2023 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$1,488,713N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
Operating Cash Flowderived-$742,518N/M ended Dec 31, 2024 · filed Mar 21, 2025 · 80 d after period end